Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27816805 | 0.86 | MEN1 (0.47) | MEN1KMT2A | |
| SCHEMBL5373262 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2AL3MBTL1FAAH | |
| SCHEMBL8485315 | 0.78 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2AL3MBTL1FAAH | |
| SCHEMBL3813779 | 0.76 | HRH3 (0.49) | GAAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL9398268 | 0.76 | OPRM1 (0.47) | LMNAGAAALDH1A1L3MBTL1 | |
| SCHEMBL133620 | 0.75 | CCR3 (0.61) | ALDH1A1CCR3 | |
| SCHEMBL2636547 | 0.73 | MEN1 (0.68) | LMNAGAAALDH1A1MEN1KMT2A | |
| SCHEMBL22081220 | 0.73 | CCR3 (0.59) | ALDH1A1CCR3CYP2C9CYP2C19MAPK14 | |
| SCHEMBL9253235 | 0.73 | CCR3 (0.43) | LMNAGAAALDH1A1MEN1KMT2A | |
| SCHEMBL8482965 | 0.73 | CYP2C9 (0.47) | LMNAGAAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100413860-C | piperidine derivatives as NMDA receptor antagonists | HUNGARY GIREL GYOGYSZERGYAR (HU) | 2008-08-27 | — | — | CN | disclosed |
| US-7365083-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-04-29 | — | — | US | disclosed |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| CN-1556805-A | piperidine derivatives as NMDA receptor antagonists | ������ҩ������˾ | 2004-12-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | LMNA 3795/4885GAA 4653/4885ALDH1A1 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.